Neptune Technologies & Bioresources Inc is on the Cruelty Free Investing list for exploiting animals because the company does animal testing for some of their medical analysis and clinical research.
The company stated in the following report that they conduct pre-clinical trials of their drugs on animals.
“The accumulated nonclinical data showed that it would be beneficial to explore in humans testing the positive results which were observed in animal testing to the effect that ONEMIA® may benefit patients taking statins dealing with complex and hard to manage lipid profiles.” (Page 8) Read the full document
Neptune Technologies & Bioresources, Inc. engages in the development and commercialization of marine derived omega-3 polyunsaturated fatty acids. It operates through three segments: Neptune, Acasti and NeuroBio. The Neptune segment involves the production and commercialization of nutraceutical products. The Acasti segment involves the development and commercialization of medical food and pharmaceutical products for cardiovascular diseases. The NeuroBio segment involves the development of medical food and pharmaceutical products for neurological diseases. The company was founded by Henri Harland on October 9, 1998 and is headquartered in Laval, Canada. [Source: MarketWatch]
Company Website: http://neptunecorp.com